EZH2 and diffuse large B-cell lymphoma: Inhibition of EZH2 enzymatic activity is currently actively evaluated in clinical trials in diffuse large B cell lymphoma and follicular lymphoma, where mutations in EZH2 affect its enzymatic and canonical function [29].